| Anemia, Sickle Cell
Casgevy vs Adakveo
Side-by-side clinical, coverage, and cost comparison for anemia, sickle cell.Deep comparison between: Casgevy vs Adakveo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAdakveo has a higher rate of injection site reactions vs Casgevy based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Adakveo but not Casgevy, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Casgevy
Adakveo
At A Glance
IV infusion
Single dose
CRISPR/Cas9 gene therapy
IV infusion
Every 4 weeks
P-selectin antagonist
Indications
- Anemia, Sickle Cell
- Transfusion dependent thalassaemia beta
- Anemia, Sickle Cell
Dosing
Anemia, Sickle Cell, Transfusion dependent thalassaemia beta One-time single IV infusion; minimum dose 3 x 10^6 CD34+ cells/kg administered 48 hours to 7 days after full myeloablative conditioning.
Anemia, Sickle Cell 5 mg/kg IV infusion over 30 minutes at Week 0, Week 2, and every 4 weeks thereafter; may be given with or without hydroxyurea.
Contraindications
—
—
Adverse Reactions
Most common (>=25%) Mucositis, febrile neutropenia, decreased appetite
Most common lab abnormalities (>=50%) Neutropenia, thrombocytopenia, leukopenia, anemia, lymphopenia
Serious Cholelithiasis, pneumonia, abdominal pain, pyrexia, sepsis (SCD); veno-occlusive liver disease, viral infection, hypoxia, thrombocytopenia (TDT)
Most common (>=10%) Arthralgia, nausea, back pain, abdominal pain, pyrexia, diarrhea, headache, fatigue, vomiting, oropharyngeal pain
Serious Pyrexia, pain
Pharmacology
CRISPR/Cas9-edited autologous cellular gene therapy; edited CD34+ hematopoietic stem cells engraft in bone marrow and differentiate to erythroid lineage cells with reduced BCL11A expression, increasing gamma-globin and fetal hemoglobin (HbF) production to address the underlying pathophysiology of sickle cell disease and transfusion-dependent beta-thalassemia.
Crizanlizumab-tmca is a P-selectin antagonist; a humanized IgG2 kappa monoclonal antibody that binds P-selectin and blocks its interactions with ligands including PSGL-1, thereby preventing adhesive interactions between endothelial cells, platelets, red blood cells, and leukocytes.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Casgevy
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
Adakveo
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Casgevy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Adakveo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Casgevy
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Adakveo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Sickle Cell Disease (SCD): Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$25/momo
Novartis Oncology Universal Co-pay Program: AdakveoCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CasgevyView full Casgevy profile
AdakveoView full Adakveo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.